Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study.
Humans
Female
Middle Aged
Male
Platelet Aggregation Inhibitors
Prasugrel Hydrochloride
Acute Coronary Syndrome
/ drug therapy
Ticagrelor
/ therapeutic use
Percutaneous Coronary Intervention
/ adverse effects
Pilot Projects
Myocardial Infarction
/ therapy
Hemorrhage
/ chemically induced
Treatment Outcome
Journal
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
ISSN: 1969-6213
Titre abrégé: EuroIntervention
Pays: France
ID NLM: 101251040
Informations de publication
Date de publication:
15 May 2023
15 May 2023
Historique:
pmc-release:
15
05
2024
medline:
15
5
2023
pubmed:
4
2
2023
entrez:
3
2
2023
Statut:
ppublish
Résumé
Early P2Y In this single-arm pilot study, we evaluated the feasibility and safety of ticagrelor or prasugrel monotherapy directly following PCI in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). Patients received a loading dose of ticagrelor or prasugrel before undergoing platelet function testing and subsequent PCI using new-generation drug-eluting stents. The stent result was adjudicated with optical coherence tomography in the first 35 patients. Ticagrelor or prasugrel monotherapy was continued for 12 months. The primary ischaemic endpoint was the composite of all-cause mortality, myocardial infarction, definite or probable stent thrombosis or stroke within 6 months. The primary bleeding endpoint was Bleeding Academic Research Consortium type 2, 3 or 5 bleeding within 6 months. From March 2021 to March 2022, 125 patients were enrolled, of whom 75 ultimately met all in- and exclusion criteria (mean age 64.5 years, 29.3% women). Overall, 70 out of 75 (93.3%) patients were treated with ticagrelor or prasugrel monotherapy directly following PCI. The primary ischaemic endpoint occurred in 3 (4.0%) patients within 6 months. No cases of stent thrombosis or spontaneous myocardial infarction occurred. The primary bleeding endpoint occurred in 7 (9.3%) patients within 6 months. This study provides first-in-human evidence that P2Y
Sections du résumé
BACKGROUND
BACKGROUND
Early P2Y
AIMS
OBJECTIVE
In this single-arm pilot study, we evaluated the feasibility and safety of ticagrelor or prasugrel monotherapy directly following PCI in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS).
METHODS
METHODS
Patients received a loading dose of ticagrelor or prasugrel before undergoing platelet function testing and subsequent PCI using new-generation drug-eluting stents. The stent result was adjudicated with optical coherence tomography in the first 35 patients. Ticagrelor or prasugrel monotherapy was continued for 12 months. The primary ischaemic endpoint was the composite of all-cause mortality, myocardial infarction, definite or probable stent thrombosis or stroke within 6 months. The primary bleeding endpoint was Bleeding Academic Research Consortium type 2, 3 or 5 bleeding within 6 months.
RESULTS
RESULTS
From March 2021 to March 2022, 125 patients were enrolled, of whom 75 ultimately met all in- and exclusion criteria (mean age 64.5 years, 29.3% women). Overall, 70 out of 75 (93.3%) patients were treated with ticagrelor or prasugrel monotherapy directly following PCI. The primary ischaemic endpoint occurred in 3 (4.0%) patients within 6 months. No cases of stent thrombosis or spontaneous myocardial infarction occurred. The primary bleeding endpoint occurred in 7 (9.3%) patients within 6 months.
CONCLUSIONS
CONCLUSIONS
This study provides first-in-human evidence that P2Y
Identifiants
pubmed: 36734020
pii: EIJ-D-22-00886
doi: 10.4244/EIJ-D-22-00886
pmc: PMC10173755
pii:
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Prasugrel Hydrochloride
G89JQ59I13
Ticagrelor
GLH0314RVC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
63-72Références
Eur Heart J Acute Cardiovasc Care. 2015 Dec;4(6):555-60
pubmed: 25267878
J Am Coll Cardiol. 2020 Feb 18;75(6):578-586
pubmed: 32057371
Eur Heart J. 2011 Dec;32(23):2945-53
pubmed: 21804104
N Engl J Med. 2007 Nov 15;357(20):2001-15
pubmed: 17982182
N Engl J Med. 2013 Jan 17;368(3):254-65
pubmed: 23323902
EuroIntervention. 2021 Sep 20;17(7):550-560
pubmed: 33840639
JACC Cardiovasc Interv. 2020 Oct 12;13(19):2251-2262
pubmed: 32950419
JACC Cardiovasc Interv. 2013 Dec;6(12):1267-74
pubmed: 24355117
Lancet. 2019 Jun 22;393(10190):2503-2510
pubmed: 31056295
JAMA. 2019 Jun 25;321(24):2414-2427
pubmed: 31237644
Expert Rev Cardiovasc Ther. 2022 Aug;20(8):637-645
pubmed: 35916833
N Engl J Med. 2019 Nov 21;381(21):2032-2042
pubmed: 31556978
N Engl J Med. 2019 Oct 17;381(16):1524-1534
pubmed: 31475799
N Engl J Med. 2009 Sep 10;361(11):1045-57
pubmed: 19717846
JACC Cardiovasc Imaging. 2015 Nov;8(11):1297-305
pubmed: 26563859
JAMA. 2019 Jun 25;321(24):2428-2437
pubmed: 31237645
J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264
pubmed: 30153967
Nat Rev Cardiol. 2018 Aug;15(8):480-496
pubmed: 29973709
Eur Heart J. 2018 Jan 14;39(3):213-260
pubmed: 28886622
JAMA Cardiol. 2022 Apr 01;7(4):407-417
pubmed: 35234821
Drugs. 2013 Oct;73(15):1681-709
pubmed: 24114622
Lancet. 2018 Sep 15;392(10151):940-949
pubmed: 30166073
Eur Heart J. 2021 Apr 7;42(14):1289-1367
pubmed: 32860058
Eur J Clin Invest. 2019 Jun;49(6):e13102
pubmed: 30882911
BMJ Open. 2019 Feb 20;9(2):e023337
pubmed: 30787079
JACC Cardiovasc Interv. 2019 Aug 26;12(16):1521-1537
pubmed: 31202949
Circulation. 2018 Jun 12;137(24):2635-2650
pubmed: 29891620
J Thromb Haemost. 2011 Mar;9(3):552-61
pubmed: 21143373
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242
J Am Coll Cardiol. 2017 Oct 10;70(15):1846-1857
pubmed: 28982497
JAMA. 2020 Jun 16;323(23):2407-2416
pubmed: 32543684